Vangroenweghe Frédéric, Allais Liesbeth, Van Driessche Ellen, van Berkel Robbert, Lammers Gerwen, Thas Olivier
Elanco, BU Food Animals, Plantijn en Moretuslei 1 - 3rd floor, 2018 Antwerpen, Belgium.
DGZ-Vlaanderen, Industrielaan 29, 8820 Torhout, Belgium.
Porcine Health Manag. 2020 Jan 16;6:1. doi: 10.1186/s40813-019-0140-y. eCollection 2020.
is the primary cause of swine dysentery, characterized by bloody to mucoid diarrhea due to mucohaemorhagic colitis in pigs and primarily affects pigs during the grow/finishing stage. Control and prevention of consists of administration of antimicrobial drugs, besides management and adapted feeding strategies. A worldwide re-emergence of the disease has recently been reported with an increasing number of isolates demonstrating decreased susceptibility to several crucially important antimicrobials in the control of swine dysentery. A novel non-antibiotic zinc chelate has been reported to demonstrate positive effects on fecal quality and consistency, general clinical signs, average daily weight gain and excretion during and after a 6-day oral treatment. The objective of the present study was to evaluate the zinc chelate (Intra Dysovinol 499 mg/ml (ID); Elanco) on naturally occurring swine dysentery due to under field conditions in the Netherlands.
Oral administration of zinc chelate resulted in improvement of general clinical signs from 3 days onwards in the ID-treated group combined with a significantly better total fecal score at 14 days post-treatment. Overall, average daily weight gain was better in the ID-treated group over the entire study period (0-14 days) and during the 8 days following the end of ID-treatment. A significant reduction (4.48 vs. 0.63 log cfu/g feces; ID-treated vs. control) in excretion was observed during the 6-day treatment period with a high percentage of animals (58.3 vs. 12.3%; ID-treated vs. control) with no excretion of from their feces. No additional antimicrobial treatment was needed in the ID-treated group, whereas 35% of the pigs in the control group were treated with an antibiotic at least once. No mortality occurred in both groups. No adverse events were reported during and following the ID-treatment.
Zinc chelate - administered as a Zn-Na-EDTA complex - is a non-antibiotic treatment for swine dysentery that reduces shedding with 4.48 log cfu/g feces within its 6-day treatment while improving general clinical signs (90.0 vs. 73.6% animals with normal score) and total fecal score within 2-4 days following administration in naturally infected pigs. The positive effects of ID treatment remain for at least 8 days after cessation of oral ID therapy. Pigs remaining in a highly contaminated environment may be re-infected following the end of ID treatment, however, this is not different to standard antimicrobial therapy. Therefore, control of swine dysentery should combine an efficacious treatment with additional management practices to reduce the environmental infection pressure in order to limit re-infection as much as possible. The ID treatment resulted in a higher growth rate and improved general health, whereas no mortality was observed and no additional therapeutic treatments were necessary in contrast to the control pigs.
[疾病名称]是猪痢疾的主要病因,其特征为猪因黏液出血性结肠炎而出现从血性到黏液性腹泻,主要影响生长/育肥阶段的猪。除管理和适应性饲养策略外,[疾病名称]的控制和预防包括使用抗菌药物。最近有报道称该疾病在全球范围内再度出现,越来越多的分离株对控制猪痢疾的几种至关重要的抗菌药物敏感性降低。据报道,一种新型非抗生素锌螯合物在为期6天的口服治疗期间及之后,对粪便质量和稠度、一般临床症状、平均日增重以及[病原体名称]排泄均显示出积极作用。本研究的目的是在荷兰的田间条件下,评估锌螯合物(Intra Dysovinol 499 mg/ml(ID);英特威)对由[病原体名称]引起的自然发生的猪痢疾的疗效。
口服锌螯合物使ID治疗组从第3天起一般临床症状得到改善,且在治疗后14天总粪便评分显著更好。总体而言,在整个研究期间(0 - 14天)以及ID治疗结束后的8天内,ID治疗组的平均日增重更佳。在为期6天的治疗期内,观察到[病原体名称]排泄显著减少(粪便中每克菌落形成单位对数:ID治疗组为4.48,对照组为0.63),且高比例动物(58.3%对12.3%;ID治疗组对对照组)粪便中无[病原体名称]排泄。ID治疗组无需额外的抗菌治疗,而对照组35%的猪至少接受过一次抗生素治疗。两组均未发生死亡。在ID治疗期间及之后均未报告不良事件。
以锌 - 钠 - 乙二胺四乙酸络合物形式给药的锌螯合物是一种治疗猪痢疾的非抗生素药物,在6天治疗期内可使[病原体名称]排泄减少4.48 log cfu/g粪便,同时改善一般临床症状(正常评分动物比例:90.0%对73.6%),并在给自然感染猪给药后2 - 4天内改善总粪便评分。口服ID治疗停止后,其积极作用至少持续8天。然而,处于高度污染环境中的猪在ID治疗结束后可能会再次感染,这与标准抗菌治疗并无不同。因此,猪痢疾的控制应将有效的治疗与额外的管理措施相结合,以降低环境感染压力,从而尽可能限制再次感染。与对照猪相比,ID治疗使生长速度更高且整体健康状况得到改善,未观察到死亡情况且无需额外的治疗。